{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"24"}],"units":"Participants"}],"groups":[{"description":"Patients will receive six doses of Uproleselan intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.","id":"OG000","title":"Uproleselan + Standard of Care Melphalan"},{"description":"Patients will receive six doses of placebo intravenously. The doses will begin the evening of Day -3 and continue every 12 hours through the morning of Day 0, prior to hematopoietic stem cell transplant (auto-HCT). On the evening of Day -2, patients also receive one dose of standard of care Melphalan intravenously.","id":"OG001","title":"Placebo + Standard of Care Melphalan"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The number of participants analyzed at each time point may differ from the overall number of participants analyzed because the data was not collected. One patient in the placebo + standard of care melphalan arm was not evaluable for the outcome measure.","reportingStatus":"POSTED","timeFrame":"Through date of discharge (upto be 18 days)","title":"Incidence of Infection Assessed by Rates of Bacteremia (With Organism Reported When Available)","type":"SECONDARY","unitOfMeasure":"Participants"}